Salonpas is a drug owned by Hisamitsu Pharmaceutical Co Inc. It is protected by 2 US drug patents filed from 2014 to 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 03, 2030. Details of Salonpas's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8809615 | Adhesive preparation |
Jan, 2030
(4 years from now) | Active |
| US9233184 | Adhesive preparation |
Aug, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Salonpas's patents.
Latest Legal Activities on Salonpas's Patents
Given below is the list of recent legal activities going on the following patents of Salonpas.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Feb, 2022 | US8809615 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2018 | US8809615 |
| Email Notification Critical | 05 Oct, 2016 | US8809615 |
| Mail-Petition Decision - Denied | 30 Sep, 2016 | US8809615 |
| Petition Decision - Denied | 29 Sep, 2016 | US8809615 |
| Post Issue Communication - Certificate of Correction | 01 Oct, 2014 | US8809615 |
| Petition Entered | 04 Sep, 2014 | US8809615 |
| Recordation of Patent Grant Mailed Critical | 19 Aug, 2014 | US8809615 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Aug, 2014 | US8809615 |
| Email Notification Critical | 01 Aug, 2014 | US8809615 |
US patents provide insights into the exclusivity only within the United States, but Salonpas is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Salonpas's family patents as well as insights into ongoing legal events on those patents.
Salonpas's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Salonpas's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 03, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Salonpas Generics:
There are no approved generic versions for Salonpas as of now.
About Salonpas
Salonpas is a drug owned by Hisamitsu Pharmaceutical Co Inc. Salonpas uses Menthol; Methyl Salicylate as an active ingredient. Salonpas was launched by Hisamitsu Pharm Co in 2008.
Approval Date:
Salonpas was approved by FDA for market use on 20 February, 2008.
Active Ingredient:
Salonpas uses Menthol; Methyl Salicylate as the active ingredient. Check out other Drugs and Companies using Menthol; Methyl Salicylate ingredient
Dosage:
Salonpas is available in patch form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3%;10% | PATCH | Over the counter | TOPICAL |